CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
Tedizoliddrug
Likely dose
Tedizolid 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03009045
NCT03009045Phase 2Completed
CompareCT.gov

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Jan 4, 2017·Updated Dec 13, 2023

In Brief

A Phase 2 clinical trial evaluating Tedizolid for Bone and Joint Infection. Completed, enrolled 44 participants across 2 sites.

Detailed Summary

The problem of interest is that doctors are looking for new antibiotic treatments for bone and joint infections. Treatment for bone and joint infection is not standardized, which allows a wide range of antibiotic therapy to potentially be given. A type of bacteria called S. aureus is the most common cause of bone and joint infection. Methicillin resistant S. aureus (MRSA) is a type of bacteria that is not killed by some antibiotics, and it is increasingly common in U.S. and non-U.S. medical centers. This problem will be studied by investigating whether an antibiotic called tedizolid is tolerable, safe and effective to treat bone and joint infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone and Joint Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 4, 2017
Enrollment StartFeb 6, 2017
Primary CompletionMar 23, 2021
Study CompletionAug 6, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 9.5 years ago

Interventions

Tedizoliddrug

200mg oral tedizolid one pill per day